Epizyme, Inc. issued a corrected version of the press release, clarifying that only the Phase 1b portion (and not the Phase 2 portion) of the Company's ongoing Phase 1b/2 clinical trial in castration-resistant prostate cancer is fully enrolled. Third subhead of release should read: Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 1b Portion of Phase 1b/2 Castration-Resistant Prostate Cancer Fully Enrolled; Initial Safety & Activity Data Expected in 2021 (instead of Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 2 Castration-Resistant Prostate Cancer Fully Enrolled; Initial Safety & Activity Data Expected in 2021).